Thomas Spires
Senior Director, Translational Medicine Bristol Myers Squibb
Tom is a seasoned leader in translational medicine and drug development with over two decades of experience spanning discovery through late-stage clinical development. Currently Senior Director at Bristol Myers Squibb, he leads translational strategies for Krazati (KRAS G12C inhibitor), directing cross-functional teams across biomarker science, diagnostics, bioinformatics, and clinical development. His prior leadership on Opdivo/Yervoy breast cancer programs and contributions to thoracic oncology and immuno-oncology pipelines underscore his depth in precision medicine and biomarker-driven trial execution. He is an inventor on multiple patents in oncology and immunotherapy, and his work has supported major regulatory submissions and high-impact publications in Nature Medicine, Clinical Cancer Research, and Annals of Oncology. Passionate about translating science into impactful therapies, he bridges discovery and development to accelerate innovative solutions for patients with cancer.
Seminars
- How does differential targeting influence tolerability and depth of pathway inhibition, and where do selective versus broader approaches ultimately succeed or fail?
- How should mutant-selective versus wild-type-sparing strategies be balanced to deepen inhibition without breaching tolerability limits, especially when layering multi-agent regimens?
- How can safety-first design principles, PK/PD-guided exposure management, mechanism-based toxicity mitigation, and early integration of safety margins, enable continuous pathway suppression and long-term disease control?
